News Releases

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms

News tagged ‘OvarianCancer’ clear

  • Ursula Matulonis, MD, the director of the Gynecological Cancer Treatment Center in the Susan F. Smith Center for Women’s Cancers at Dana-Farber receives a $900,000 grant from the Ovarian Cancer Research Foundation (OCRF) to test new combinations of targeted drugs against the disease.

Tags: Grants, OvarianCancer, GynecologicCancers

  • Dana-Farber scientists identify a genetic flaw that drives some ovarian cancers, which could assist in identifying treatments for ovarian cancer patients.

Tags: Genomics, OvarianCancer, GynecologicCancers

  • Ursula Matulonis, MD, director of the Gynecologic Oncology Program in the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute, says there are three things that every woman should know about ovarian cancer — known as the silent killer.

Tags: OvarianCancer, GynecologicCancers

  • A novel pairing of two cancer drug types showed promising activity and had manageable toxicities, according to a first-of-its-kind clinical trial led by scientists at Dana-Farber Cancer Institute.

Tags: BreastCancer, OvarianCancer, GynecologicCancers

  • Dana-Farber researchers find novel antibody-guided drug achieves responses in platinum drug-resistant ovarian cancer.

Tags: OvarianCancer, GynecologicCancers

  • A new study that proposes a three-in-one test for gynecologic cancers underscores the promise of molecular screening for early detection of endometrial and ovarian cancers, but also suggests that such tests are not yet ready for clinical use. Andrea Myers, MD, PhD, a co-author of the commentary on the study, says the test is an important step in that direction.

Tags: CervicalCancer, OvarianCancer, Prevention, GynecologicCancers

  • Research led by Dana-Farber Cancer Institute scientists may soon enable doctors to determine which patients with the most common form of ovarian cancer – high-grade serous ovarian cancer (HGSOC) – are most likely to benefit from a certain class of drugs.

Tags: OvarianCancer, GynecologicCancers

  • Dana-Farber/Brigham and Women's Cancer Center and the Massachusetts Ovarian Cancer Awareness Coalition want women to get the facts and recognize the signs of the disease.

Tags: OvarianCancer, GynecologicCancers

  • Scientists from Brigham and Women's Hospital and Dana-Farber Cancer Institute and their colleagues have found a genetic marker that predicts which aggressive "triple negative" breast cancers and certain ovarian cancers will likely respond to platinum-based chemotherapies.

Tags: BasicResearch, BreastCancer, Genomics, OvarianCancer, GynecologicCancers

  • The discovery of a subtype of ovarian cancer that could account for up to one-third of all serous ovarian cancers may lead to clinical trials using anti-angiogenic drugs that are already being tested in other cancers.

Tags: OvarianCancer, GynecologicCancers

Showing 1-10 of 18 items